159 related articles for article (PubMed ID: 32128875)
1. Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care.
Hinton W; Feher M; Munro N; Joy M; de Lusignan S
Diabet Med; 2020 Sep; 37(9):1499-1508. PubMed ID: 32128875
[TBL] [Abstract][Full Text] [Related]
2. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
[TBL] [Abstract][Full Text] [Related]
3. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
Wittbrodt E; Chamberlain D; Arnold SV; Tang F; Kosiborod M
Diabetes Obes Metab; 2019 Aug; 21(8):1985-1989. PubMed ID: 30968543
[TBL] [Abstract][Full Text] [Related]
4. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
[TBL] [Abstract][Full Text] [Related]
5. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
[TBL] [Abstract][Full Text] [Related]
6. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
[TBL] [Abstract][Full Text] [Related]
7. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
8. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
[TBL] [Abstract][Full Text] [Related]
9. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
10. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.
Smidt LCA; Visseren FLJ; de Ranitz-Greven WL; Nathoe HM; Kappelle LJ; de Borst GJ; de Valk HW; Westerink J;
Cardiovasc Diabetol; 2021 Sep; 20(1):181. PubMed ID: 34496847
[TBL] [Abstract][Full Text] [Related]
11. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
[TBL] [Abstract][Full Text] [Related]
12. How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol.
Hinton W; Feher MD; Munro N; de Lusignan S
Diabetes Ther; 2019 Jun; 10(3):1163-1170. PubMed ID: 31041781
[TBL] [Abstract][Full Text] [Related]
13. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
[TBL] [Abstract][Full Text] [Related]
14. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
17. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
18. Impact of breakthrough trials on prescription trends of sodium-glucose cotransporter-2 inhibitors in Japan: An interrupted time-series analysis.
Iketani R; Imai S
J Clin Pharm Ther; 2022 Nov; 47(11):1796-1804. PubMed ID: 36068684
[TBL] [Abstract][Full Text] [Related]
19. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
20. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
